AU2018361561C1 - Method for expansion of lymphocytes - Google Patents

Method for expansion of lymphocytes Download PDF

Info

Publication number
AU2018361561C1
AU2018361561C1 AU2018361561A AU2018361561A AU2018361561C1 AU 2018361561 C1 AU2018361561 C1 AU 2018361561C1 AU 2018361561 A AU2018361561 A AU 2018361561A AU 2018361561 A AU2018361561 A AU 2018361561A AU 2018361561 C1 AU2018361561 C1 AU 2018361561C1
Authority
AU
Australia
Prior art keywords
antigen
expansion
cells
tumor
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018361561A
Other languages
English (en)
Other versions
AU2018361561B2 (en
AU2018361561A1 (en
Inventor
Sara BOBISSE
George Coukos
Alexandre Harari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd filed Critical Ludwig Institute for Cancer Research Ltd
Publication of AU2018361561A1 publication Critical patent/AU2018361561A1/en
Publication of AU2018361561B2 publication Critical patent/AU2018361561B2/en
Application granted granted Critical
Publication of AU2018361561C1 publication Critical patent/AU2018361561C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1107—B cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
AU2018361561A 2017-11-06 2018-11-06 Method for expansion of lymphocytes Active AU2018361561C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582163P 2017-11-06 2017-11-06
US62/582,163 2017-11-06
PCT/EP2018/080343 WO2019086711A1 (en) 2017-11-06 2018-11-06 Method for expansion of lymphocytes

Publications (3)

Publication Number Publication Date
AU2018361561A1 AU2018361561A1 (en) 2020-05-07
AU2018361561B2 AU2018361561B2 (en) 2025-01-30
AU2018361561C1 true AU2018361561C1 (en) 2025-07-03

Family

ID=64332272

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018361561A Active AU2018361561C1 (en) 2017-11-06 2018-11-06 Method for expansion of lymphocytes

Country Status (7)

Country Link
US (1) US20200338125A1 (enExample)
EP (1) EP3707245A1 (enExample)
JP (1) JP7357613B2 (enExample)
CN (1) CN111801415A (enExample)
AU (1) AU2018361561C1 (enExample)
CA (1) CA3081479A1 (enExample)
WO (1) WO2019086711A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3118186A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-.beta.1 specific antibodies and methods and uses thereof
AU2019374496B2 (en) 2018-11-05 2026-02-05 Centre Hospitalier Universitaire Vaudois Humanized and variant TGF-β3 specific antibodies and methods and uses thereof
AU2020304022A1 (en) * 2019-06-24 2022-02-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
BR112022011702A2 (pt) * 2019-12-18 2022-09-06 Cbio As Processo melhorado para cultura de linfócitos infiltrantes tumorais para uso terapêutico
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
WO2021239083A1 (zh) * 2020-05-29 2021-12-02 上海君赛生物科技有限公司 肿瘤浸润淋巴细胞的种子细胞培养基及其应用
KR20230065251A (ko) 2020-08-07 2023-05-11 네오진 테라퓨틱스 비.브이. 유전적으로 조작된 t 세포를 풍부화시키기 위한 방법
JP2023538364A (ja) * 2020-08-17 2023-09-07 ノースウェスタン ユニバーシティ 膠芽細胞腫および他のがんの処置のためのｂ細胞ベースの免疫治療
CN116948964A (zh) 2020-11-19 2023-10-27 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的培养方法及其用途
CN112501308B (zh) * 2020-11-30 2025-10-10 中国水产科学研究院珠江水产研究所 一组鳖科动物线粒体全基因组扩增通用引物
WO2022135525A1 (zh) * 2020-12-24 2022-06-30 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的制备方法及其用途
CN114686430A (zh) * 2020-12-31 2022-07-01 上海赛比曼生物科技有限公司 一种制备til的方法
KR20230146538A (ko) * 2021-01-20 2023-10-19 네오진 테라퓨틱스 비.브이. 조작된 항원 제시 세포
CN115315509B (zh) * 2021-02-08 2024-05-07 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的制备方法及其用途
CN117321189A (zh) * 2021-04-30 2023-12-29 泰根制药有限公司 淋巴细胞的单血管扩增
US20240207319A1 (en) 2021-05-06 2024-06-27 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
AU2022299605A1 (en) * 2021-06-22 2024-01-04 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells
US20240360410A1 (en) * 2021-08-03 2024-10-31 Suzhou Grit Biotechnology Co., Ltd. Modified tumor infiltrating lymphocyte and use thereof
US20240382591A1 (en) * 2021-09-21 2024-11-21 The University Of Chicago Methods and composition using patient-derived autologous neoantigens for treating cancer
CN115433713B (zh) * 2022-03-03 2023-10-27 中山大学孙逸仙纪念医院深汕中心医院 一种自体肿瘤引流淋巴结淋巴细胞的制备方法及其应用
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
WO2025081198A1 (en) * 2023-10-13 2025-04-17 Northwestern University B cell production and expansion
WO2025131119A1 (en) * 2023-12-22 2025-06-26 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017723A1 (en) * 2011-12-12 2015-01-15 Cell Medica Limited Process of expanding t cells

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
BR0108545A (pt) 2000-02-24 2004-06-29 Xcyte Therapies Inc Estimulação e concentração simultâneas das células
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
DE60236520D1 (de) 2001-08-16 2010-07-08 Univ Pennsylvania Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
EP1995316A1 (de) 2007-05-25 2008-11-26 Qiagen GmbH Verfahren zur schonenden Zellaufreinigung, Zellgewinnung und Transfektion von Zellen
EP2009095A1 (en) 2007-06-28 2008-12-31 Innovalor AG Method of generating glucose-responsive cells
WO2009094273A2 (en) 2008-01-15 2009-07-30 Yale University Compositions and methods for adoptive and active immunotherapy
CN101824400B (zh) * 2009-03-05 2012-08-08 中国科学院微生物研究所 一种放大增殖抗原特异性t细胞的方法
US8383099B2 (en) * 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
KR102095670B1 (ko) * 2010-05-14 2020-03-31 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
US10023657B2 (en) 2010-10-01 2018-07-17 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
US20170107490A1 (en) * 2014-06-11 2017-04-20 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
US10987412B2 (en) * 2014-09-17 2021-04-27 The John Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells
US10973894B2 (en) * 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
US11723962B2 (en) * 2016-05-04 2023-08-15 Fred Hutchinson Cancer Center Cell-based neoantigen vaccines and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017723A1 (en) * 2011-12-12 2015-01-15 Cell Medica Limited Process of expanding t cells

Also Published As

Publication number Publication date
WO2019086711A1 (en) 2019-05-09
JP7357613B2 (ja) 2023-10-06
CN111801415A (zh) 2020-10-20
AU2018361561B2 (en) 2025-01-30
AU2018361561A1 (en) 2020-05-07
US20200338125A1 (en) 2020-10-29
EP3707245A1 (en) 2020-09-16
JP2021501596A (ja) 2021-01-21
CA3081479A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
AU2018361561B2 (en) Method for expansion of lymphocytes
AU2022201222B2 (en) Delivery of biomolecules to immune cells
Tian et al. 5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING
US20210382068A1 (en) Hla single allele lines
US20190247432A1 (en) Genetically Modified Immune Cells Targeting NY-ESO-1 and Methods of Use Thereof
US20220170097A1 (en) Car t cell transcriptional atlas
US20250145953A1 (en) Use of histone modifiers to reprogram effector t cells
US20220226380A1 (en) Gene knock-outs to improve t cell function
US20240327491A1 (en) T cell receptors specific for tumor-associated antigens and methods of use thereof
WO2022226101A1 (en) Methods and compositions for genetic modification and therapeutic use of immune cells
Santa et al. Functional avidity–driven activation-induced cell death shapes CTL immunodominance
WO2023049733A2 (en) Methods and composition using patient-derived autologous neoantigens for treating cancer
CA3258639A1 (en) Multispecific molecules to modulate T lymphocyte activity, and their uses
HK40030363A (en) Method for expansion of lymphocytes
KR20240075776A (ko) 유도 만능 줄기 세포-기반 암 백신
KR20120054018A (ko) 일과성 생착 ｃｔｌ을 포함하는 의약품 조성물
JP6508873B2 (ja) 抗原特異的ｔ細胞受容体の取得方法
CA3077085C (en) Screening of t lymphocytes for cancer-specific antigens
Gao T and B cell collaboration in response to vaccination
WO2023225512A2 (en) Methods for optimizing t cell immunotherapeutic effector and memory function
Diken et al. CIMT 2014: Next waves in cancer immunotherapy-Report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 MAR 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 19 MAR 2025

FGA Letters patent sealed or granted (standard patent)